A man in his 60s developed reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin (iBCG) for papillary carcinoma of bladder. Evaluation revealed leucocytosis and raised inflammatory markers. HLA B27 was positive. Based on the temporal relationship, it was attributed to BCG-related reactive arthritis. iBCG was stopped. Treatment with non-steroidal anti-inflammatory drugs (NSAIDS) and glucocorticoids were ineffective. Prolonged course of disease-modifying antirheumatic drugs (DMARDS) was required which aided in alleviation of symptoms and sustained remission. Intravesical BCG therapy is a treatment for bladder cancer. It is rarely associated with reactive arthritis, which responds to discontinuation of iBCG and treatment with NSAIDS and/or short-term glucocorticoids. iBCG-related reactive arthritis commonly has an acute/subacute course. Chronic arthritis as observed in our case requiring prolonged treatment with DMARDS is rare.
Vasculitis is a group of heterogeneous conditions characterised by inflammation of blood vessels. Based on the predominant size of the affected vessel, vasculitis is classified into small, medium, and large vessel vasculitis (LVV). Giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) are the two major types of LVV. GCA was thought to affect only the external carotid artery and its branches, whereas, TAK was thought to affect the aorta and its major branches. Advances in imaging techniques have led to a better understanding of these conditions. It has become increasingly clear that GCA can involve the aorta and its branches. GCA and TAK have overlapping features like propensity to affect the aorta and its branches, similar histopathology, and similar clinical features. However, there are differences in age, geographic location, genetics, and predominant vascular territory involvement. There are subtle differences in clinical features. Are these conditions different ends of the same spectrum or different conditions with similar features? This review compares and contrasts these two conditions based on epidemiology, genetics, pathology, predominant vascular territory involvement, and any differential response to treatment. Based on current evidence, GCA and TAK seem to be distinct conditions and not different ends of the same spectrum.